Savic · BioFactors (Oxford, England) 2024 · Controlled animal experiment · n=?

Sulforaphane prevents diabetes-induced hepatic ferroptosis by activating Nrf2 signaling axis.

Cited 20 times in the scientific literature.

Level 5 - mechanism / opinion, no new human data

Preclinical animal laboratory study

PubMed 38299761 · doi:10.1002/biof.2042 · record verified 2026-08-30

What was done

Male C57BL/6 mice were allocated to four experimental groups: vehicle-treated control, streptozotocin-induced diabetic (40 mg/kg, days 1–5), diabetic treated with sulforaphane (2.5 mg/kg, days 1–42), and non-diabetic treated with sulforaphane (2.5 mg/kg, days 1–42). The authors measured markers of Nrf2 pathway activation, antioxidant defense enzymes, iron metabolism proteins (FTH1, ferroportin 1), glutathione synthesis and recycling pathways, ferritinophagy, labile iron, lipid peroxidation products (4-HNE, lipofuscin), liver damage indices (ALT, AST, fibrosis), and serum glucose and triglycerides.

What was found

The abstract reports directional effects without providing numerical values or effect sizes. Sulforaphane treatment in diabetic mice reversed Nrf2 inactivation and upregulated downstream antioxidant, iron-handling, and glutathione-related enzymes. Sulforaphane also increased glutathione levels, reduced ferritinophagy, decreased labile iron accumulation and lipid peroxides, lowered ALT and AST, reduced liver fibrosis, and significantly decreased serum glucose and triglyceride levels compared to untreated diabetic mice.

Why it matters

This study provides in vivo mechanistic evidence that sulforaphane counteracts diabetes-associated hepatic ferroptosis and oxidative stress through activation of the Nrf2 pathway.

Limits

The study was conducted entirely in a single chemically induced (streptozotocin) mouse model of diabetes, with no human data. Specific sample sizes per group, quantitative measurements, and variance estimates were omitted from the abstract. Findings cannot be directly translated to clinical outcomes or human dosing.

Cited by